XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

pharmaphorum

JULY 25, 2022

The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab, along with talquetamab which binds to CD3 and GPRC5D.

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

MAY 17, 2021

Empaveli’s label covers treatment-naïve PNH patients as well as those who want to switch from Soliris or Ultomiris, and is based on the phase 3 PEGASUS trial in 80 patients which compared the drug to Soliris over a 16-week period. The post Apellis set to take on Alexion as FDA clears PNH drug Empaveli appeared first on.

Drugs 52

Drugs FDA Approval Marketing Clinical Trials 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Results suggest durable epigenetic re-wiring and provide rationale for intermittent clinical dosing.

Development 52

Development Drugs Clinical Development Antibody 52

pharmaphorum

DECEMBER 2, 2020

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as a chemist with Erhart’s training as a confectioner. The “first industrial war” involved drug producers as much as weapons manufacturers. It was a success, and set the pattern for the company’s future development.

Sales 128

Sales Production Drugs Marketing 128

pharmaphorum

JUNE 2, 2022

R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ It is estimated that between 3.5

Drugs 52

Drugs Sales Marketing Development 52

pharmaphorum

JANUARY 21, 2022

It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance.

Medicine 52

Medicine Marketing Manufacturing Production 52

XTalks

DECEMBER 21, 2022

This included greater adoption and acceptance of decentralized clinical trial models, emphasis on patient-centric approaches in trials, growing digitization of healthcare and dealing with drug manufacturing challenges. Here are some of the top life science trends and topics from 2022. Gene Therapy Approvals. million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

pharmaphorum

MARCH 27, 2022

Both CAR-Ts are directed at BCMA, a biomarker for multiple myeloma also targeted by GlaxoSmithKline’s approved antibody-drug conjugate Blenrep (belantamab mafodotin) and J&J’s experimental bispecific antibody teclistamab, which was submitted for approval in Europe last month.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

pharmaphorum

FEBRUARY 26, 2021

Some of the most well-known Janssen products include diarrhoea treatment, Immodium (loperamide), antipsychotic Risperdal (risperidone) and Alzheimer’s disease drug, Reminyl (galantamine). billion deal to buy Momenta meant that J&J added potential inflammatory disease blockbuster nipocalimab to the pipeline at Janssen.

Sales 126

Sales Production Pharma Companies Marketing 126